Cambrex CF-MAOS Technology Wins 2009 Silver Innovation Award
Jayne Muir, Ph.D., Market Research and New Technologies
+44 1223 237 527
Stephanie LaFiura, Investor Relations Associate
East Rutherford, NJ - Cambrex Corporation (NYSE: CBM, 'Cambrex") announced today that it won the Silver Innovation Award at the 2009 CPhI Event for its Continuous-Flow Microwave-Assisted Organic Synthesis (CFMAOS) technology. The award was accepted by Dr. Jayne E. Muir (Market Research & New Technologies - Europe), who presented the technology to a panel of judges at this important pharmaceutical ingredients exhibition in Madrid, Spain on October 13, 2009.
The CPhI Innovation Awards give companies the chance to showcase the best of their R&D efforts and are widely recognized as premier awards in the field of international pharmaceutical manufacturing. This year had a particularly strong number and quality of entries and the six shortlisted companies spanned a wide range of subjects, from biopolymers to colors and coatings. On accepting the award, Dr. Muir said, "The area of flow chemistry is very exciting at the moment, and we were pleased with the interest and number of questions about the CaMWave(TM) technology following the presentation and throughout CPhI."
The CF-MAOS technology represents a dual technological breakthrough, allowing both the scale-up of microwave-assisted chemistry and the handling of heterogeneous mixtures in continuous-flow. This new technology will finally bring the benefits of both technologies out of the laboratory and into production. The CaMWave(TM) KiloLAB flow reactor is capable of manufacturing in excess of 20 kilograms of product per day, and larger reactors will generate more than one hundred metric tons of product per year. This versatile technology facilitates faster, cleaner, more reliable reactions, leading to improved productivity and lower manufacturing costs.
If you would like to inquire further about this technology, please contact Dr. Jayne E. Muir at +44 (0)1223 237527 or email@example.com.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.